Firebrick Pharma’s Nasodine Nasal Spray Phase 3 Trial Results Published

Firebrick Pharma Limited ( (AU:FRE) ) just unveiled an update.

Firebrick Pharma Limited announced the publication of its Phase 3 clinical trial results for Nasodine Nasal Spray in a high-impact journal, confirming its efficacy and safety as a treatment for the common cold. The study, which showed a 40% reduction in cold severity when treatment began within 24 hours of symptom onset, supports Nasodine’s potential as a significant treatment option, enhancing its marketability to healthcare professionals globally.

More about Firebrick Pharma Limited

Firebrick Pharma is a pharmaceutical innovator focused on developing and commercializing novel formulations and uses of povidone-iodine (PVP-I). The company has developed Nasodine® Nasal Spray (0.5% PVP-I) and is expanding its market presence with recent introductions in the United States, Singapore, Fiji, and the South Pacific, along with plans to launch in the Philippines.

Average Trading Volume: 56,078

Technical Sentiment Signal: Sell

For an in-depth examination of FRE stock, go to TipRanks’ Stock Analysis page.